齐宪荣教授团队在基因编辑与免疫治疗递送研究中取得进展

中国药学(英文版) ›› 2022, Vol. 31 ›› Issue (1): 69-70.

齐宪荣教授团队在基因编辑与免疫治疗递送研究中取得进展

北京大学药学院

北京大学药学院

收稿日期:2022-01-05 修回日期:2022-01-05 接受日期:2022-01-05 出版日期:2022-01-12 发布日期:2022-01-13

The group of Professor Xianrong Qi has made progress in gene editing and immunotherapy delivery research

School of Pharmaceutical Sciences, Peking University Health Science Center

School of Pharmaceutical Sciences, Peking University Health Science Center

Received:2022-01-05 Revised:2022-01-05 Accepted:2022-01-05 Online:2022-01-12 Published:2022-01-13

摘要/Abstract

摘要：

2021年12月25日, 纳米领域国际权威学术期刊《Nano today》(IF = 20.722)在线发表了药学院药剂学系齐宪荣教授团队题为“CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy”(利用CRISPR技术原位改造肿瘤细胞以重塑巨噬细胞实现有效的肿瘤免疫治疗)的研究成果。

Supporting:

北京大学药学院. 齐宪荣教授团队在基因编辑与免疫治疗递送研究中取得进展[J]. 中国药学(英文版), 2022, 31(1): 69-70.

School of Pharmaceutical Sciences, Peking University Health Science Center. The group of Professor Xianrong Qi has made progress in gene editing and immunotherapy delivery research[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(1): 69-70.